WHAT YOU NEED TO KNOW: DID YOU KNOW: The Inter Partes Review (IPR) Process is a Low-Cost Alternative to Traditional Patent Litigation and is Regularly Used to Knock Down Erroneously Issued Patents? Bad patents hold up generic and biosimilar drug competition and keep prices high, costing billions every year.  Thankfully, IPR was created as part […]

Continue Reading

WHAT YOU NEED TO KNOW: CAPA Releases Statement on Nomination of Kathi Vidal as Director of the U.S. Patent and Trademark Office (USPTO) “The USPTO will play a significant role in expanding access to affordable life-saving medications for millions of American patients, and CAPA looks forward to working with Kathi Vidal to ensure tackling patent […]

Continue Reading

WHAT YOU NEED TO KNOW: CAPA Applauds Introduction of the “Restoring the America Invents Act” Targeting Patent Abuse CAPA released a statement commending Senator Patrick Leahy (D-VT) and Senator John Cornyn (R-TX) on the introduction of the “Restoring the America Invents Act” to reform the U.S. patent system and strengthen tools within the U.S. Patent […]

Continue Reading

WHAT YOU NEED TO KNOW: CAPA Highlights 10th Anniversary of the America Invents Act and the Creation of the Inter Partes Review (IPR) Process Since its creation, IPR has saved over $2 billion in deadweight loss by reducing the cost of determining patent validity and has also been used to invalidate patents that were weaponized […]

Continue Reading

RECAP: CAPA Called on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit.   “Today, millions of patients and families are increasingly impacted by high drug prices while some Big Pharma companies continue abusing the U.S. patent system through anti-competitive tactics that hurt American patients.  By allowing the […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Calls on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit Recently, the U.S. Court of Appeals for the Federal Circuit upheld the verdict in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., subjecting Teva to a $234 million judgment that includes […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Points To Patent Quality As Key To Ultimately Lowering Prescription Drug Prices In a recent op-ed as part of Patent Quality Week, CAPA Executive Director Matthew Lane outlined the ways in which the pharmaceutical marketplace is impacted by Big Pharma’s manipulation and abuse of the U.S. patent system. Particularly, Lane dives […]

Continue Reading

WHAT YOU NEED TO KNOW TUESDAY, JULY 20: The Coalition Against Patent Abuse (CAPA) is hosting a panel with the Public Interest Patent Law Institute highlighting how patent law can impact every American, particularly when it comes to high drug prices. The event will feature a discussion moderated by CAPA Executive Director Matthew Lane and include the […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse’s Executive Director Matthew Lane penned an op-ed in Morning Consult recently on the need to address patent abuse and anti-competitive pricing tactics used by some major pharmaceutical companies. In his op-ed, Mr. Lane dives into the current imbalance between rewarding new drug innovations and competition from low-cost alternatives.  […]

Continue Reading

WHAT YOU NEED TO KNOW Have You Heard? The Coalition Against Patent Abuse (CAPA) is Fighting Against Anti-Competitive Tactics Used by Some Major Pharmaceutical Companies to Keep Competition Out, Prices High. In a mini-series called, “Spot-On Savings,” CAPA outlined how the U.S. Patent and Trademark Office (USPTO), through its inter partes review (IPR) process, can generate […]

Continue Reading